Component

Serum menaquinone-7 concentration

Serum menaquinone-7 concentration. Species, exposure and limitations are retained in each linked claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Serum MK-7 peaked six hours after the single dose, remained detectable to 48 hours, and rose during seven-day dosing.

    Menaquinone-7 / MK-7 → Serum menaquinone-7 concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/k2-research/23140417.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e72bb9c0cc5800cba0605d7abba2c4e6c113dda5fa0e9b4a3afff898b23a97c4", "start_char": 0, "end_char": 1328, "text_sha256": "e72bb9c0cc5800cba0605d7abba2c4e6c113dda5fa0e9b4a3afff898b23a97c4"}
    experimental_model
    Single-dose and seven-day nutritional-dose comparison
    exposure
    420 micrograms single dose or 60 micrograms/day for seven days; MK-4 versus MK-7
    limitations
    Small parallel groups; equal mass is not equal molar dose. Undetectable serum MK-4 does not prove absent absorption, absent tissue delivery or clinical ineffectiveness.
    nutrient_topic
    Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect. · Vitamin K2 / menaquinone family
    organism
    Healthy young Japanese women
    plain_language
    This K2 form remained measurable in blood across a longer sampling window.
    primary_references
    [k2-p23140417] Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. (2012). https://pubmed.ncbi.nlm.nih.gov/23140417/ DOI: 10.1186/1475-2891-11-93
    tissue_or_cell_type
    Serum vitamin K concentrations

    Vitamin K2: menaquinone forms, carboxylation, recycling and nutrient interactions (2026-09-17) · lines 266–277

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Single-dose and seven-day nutritional-dose comparison · source_derived_draft · unverified_draft

    ### k2-mk7-serum Serum MK-7 peaked six hours after the single dose, remained detectable to 48 hours, and rose during seven-day dosing. Condition category: normal nutrient_topic: Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect. plain_language: This K2 form remained measurable in blood across a longer sampling window. organism: Healthy young Japanese women tissue_or_cell_type: Serum vitamin K concentrations experimental_model: Single-dose and seven-day nutritional-dose comparison limitations: Small parallel groups; equal mass is not equal molar dose. Undetectable serum MK-4 does not prove absent absorption, absent tissue delivery or clinical ineffectiveness. exposure: 420 micrograms single dose or 60 micrograms/day for seven days; MK-4 versus MK-7 evidence_span: {"source_cache": "artifacts/k2-research/23140417.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "e72bb9c0cc5800cba0605d7abba2c4e6c113dda5fa0e9b4a3afff898b23a97c4", "start_char": 0, "end_char": 1328, "text_sha256": "e72bb9c0cc5800cba0605d7abba2c4e6c113dda5fa0e9b4a3afff898b23a97c4"} [k2-p23140417] Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women. (2012). https://pubmed.ncbi.nlm.nih.gov/23140417/ DOI: 10.1186/1475-2891-11-93
    Complete structured claim and evidence

  2. Median plasma MK-7 increased from 0.50 to 6.56 micrograms/L in the active-treatment group.

    Menaquinone-7 / MK-7 → Serum menaquinone-7 concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/k2-research/42268593.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "8bd6d3cb0722f549b8a9c8f06feba3165dfd421c4ce0658b75b90a6e64e84a4b", "start_char": 0, "end_char": 2890, "text_sha256": "8bd6d3cb0722f549b8a9c8f06feba3165dfd421c4ce0658b75b90a6e64e84a4b"}
    experimental_model
    Two-year randomized placebo-controlled VitaK-CAC trial
    exposure
    MK-7 360 micrograms/day; baseline CAC 50–400
    limitations
    Published 2026; imaging surrogate, not demonstrated fewer infarctions, improved plaque stability or arterial calcium removal. One author disclosed grants from Gnosis and shares in Coagulation Profile outside this work.
    nutrient_topic
    Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect. · Vitamin K2 / menaquinone family
    organism
    180 randomized symptomatic coronary-disease patients; 85 received MK-7 and 82 placebo
    plain_language
    The trial documented exposure as well as its imaging outcome.
    primary_references
    [k2-p42268593] Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/42268593/ DOI: 10.1001/jamacardio.2026.1279
    tissue_or_cell_type
    Coronary CT calcium score and calcium mass

    Vitamin K2: menaquinone forms, carboxylation, recycling and nutrient interactions (2026-09-17) · lines 1241–1252

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Two-year randomized placebo-controlled VitaK-CAC trial · source_derived_draft · unverified_draft

    ### k2-vitak-exposure Median plasma MK-7 increased from 0.50 to 6.56 micrograms/L in the active-treatment group. Condition category: normal nutrient_topic: Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect. plain_language: The trial documented exposure as well as its imaging outcome. organism: 180 randomized symptomatic coronary-disease patients; 85 received MK-7 and 82 placebo tissue_or_cell_type: Coronary CT calcium score and calcium mass experimental_model: Two-year randomized placebo-controlled VitaK-CAC trial limitations: Published 2026; imaging surrogate, not demonstrated fewer infarctions, improved plaque stability or arterial calcium removal. One author disclosed grants from Gnosis and shares in Coagulation Profile outside this work. exposure: MK-7 360 micrograms/day; baseline CAC 50–400 evidence_span: {"source_cache": "artifacts/k2-research/42268593.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "8bd6d3cb0722f549b8a9c8f06feba3165dfd421c4ce0658b75b90a6e64e84a4b", "start_char": 0, "end_char": 2890, "text_sha256": "8bd6d3cb0722f549b8a9c8f06feba3165dfd421c4ce0658b75b90a6e64e84a4b"} [k2-p42268593] Two Years of Menaquinone-7 Supplementation and Coronary Artery Calcification: A Randomized Clinical Trial. (2026). https://pubmed.ncbi.nlm.nih.gov/42268593/ DOI: 10.1001/jamacardio.2026.1279
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards